Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 551 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06356012RecruitingPhase 4
Imiquimod for high-risk HPV cervical lesions
This trial tests if imiquimod cream can help clear high-grade cervical lesions caused by high-risk HPV. It may be an option for people who want to avoid surgery.
BarretosAges 25–45 - NCT06523959RecruitingPhase 4
Blood clot prevention in abdominal or pelvic surgery
This trial tests whether a medication called apixaban (a blood thinner) can safely prevent blood clots after abdominal or pelvic surgery. It is for people who have a moderate risk of clots and bleeding, and who are not taking other blood thinners.
HelsinkiAges 18 years+ - NCT05301101Recruiting
Re-irradiation planning for tumors near previously treated organs
This study tests a more personalized way to plan “re-irradiation,” meaning giving radiation again in an area that was already treated before. It aims to better calculate organ risk to reduce harmful side effects while treating cancer.
Milwaukee, WisconsinAges 18 years+ - NCT07126990Enrolling by invitationPhase 1/Phase 2
A new virus therapy for untreated high-grade glioma
This trial tests a modified virus that may help treat a type of brain cancer called high-grade glioma. It is for patients who have not yet had any treatment for their tumor.
Beijing, Chaoyang DistrictAges 18–80 - NCT07369076RecruitingPhase 1/Phase 2
Testing NB-4746 for people with ALS
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
Concord, New South WalesAges 18–80 - NCT03264352RecruitingPhase 4
Treatment for slightly high blood pressure in type 2 diabetes
This trial tests an intervention to help adults with type 2 diabetes who have “high-normal” blood pressure (not severely high). If you qualify, you may learn whether this approach improves blood pressure and related health outcomes over time.
Guangzhou, GuangdongAges 45–79 - NCT07412262RecruitingPhase 2
Study of chidamide and ivonescimab for advanced lung cancer after immunotherapy resistance
This trial tests a combination of two drugs (chidamide and ivonescimab) for people with advanced non-small cell lung cancer that stopped responding to initial immunotherapy and has a specific protein marker (YAP) at high levels. It aims to see if this new combination can help when standard immunotherapy no longer works.
Guangzhou, GuangdongAges 18 years+ - NCT06214143RecruitingPhase 1/Phase 2
T3011 plus immunotherapy for advanced solid tumors
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
AnyangAges 18 years+ - NCT04458545RecruitingPhase 1/Phase 2
Opioid vaccine study for adults with heroin or fentanyl use
This trial tests a vaccine made from parts designed to help the body respond to opioids (heroin or fentanyl). It is mainly for adults with moderate-to-severe opioid use disorder who are using opioids that match the study dosing needs and who are willing to do frequent visits over about a year.
Eatontown, New JerseyAges 18–59 - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT06913309Recruiting
Home bright light therapy for teen depression
This study tests whether a bright light therapy device you can use at home can help improve depression symptoms in teenagers aged 13-17. It compares the results of using the light with a non-active placebo device.
Beijing, Beijing MunicipalityAges 13–17 - NCT05717153RecruitingEarly Phase 1
Test drugs through the tumor to study brain tumor metabolism
This early-phase study tests two drugs (DFMO and AMXT 1501) given directly into the tumor to see how they affect tumor biology and metabolism. Researchers may learn whether this approach could be safer and helpful for people with diffuse or high-grade glioma.
Rochester, MinnesotaAges 18 years+ - NCT05030298RecruitingPhase 1
Pre-op focused radiation for aggressive brain tumor
This early-phase study tests a type of very targeted radiation given before surgery for people with a high-grade (aggressive) brain tumor. The goal is to see if this approach is safe and potentially improves treatment, while collecting tumor and blood samples for research.
Phoenix, ArizonaAges 18 years+ - NCT06586203Recruiting
Genomic test to guide diabetes heart and kidney care
This study is testing whether a special blood test (genomic predictor) can help doctors better manage heart and kidney risks in people with type 2 diabetes. You may benefit from learning your personal risk score and getting more tailored care.
Montreal, QuebecAges 18 years+ - NCT07510308RecruitingPhase 1
Vaccine trial for advanced colorectal cancer
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
Chengdu, SichuanAges 18–75 - NCT07616934RecruitingPhase 1
Safety and immune response study of VAX-A1 vaccine in healthy young adults
This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.
Adelaide, South AustraliaAges 18–40 - NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT05953350RecruitingPhase 1/Phase 2
Hydroxychloroquine plus CDK4/6 medicine for advanced solid tumors
This trial tests whether adding hydroxychloroquine (a medicine that affects a cell recycling process called autophagy) can boost the anti-cancer effect of high-dose CDK4/6 inhibitor treatment in advanced solid tumors. It may help tumors respond better after prior CDK4/6 treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06702449RecruitingPhase 1/Phase 2
UTI vaccine safety and immune response study for adults 18-64
This trial tests a new vaccine to prevent urinary tract infections (UTIs). It first checks safety and immune response in healthy adults, then in women with recent E. coli UTIs. The goal is to see if the vaccine can reduce future infections.
Lenexa, KansasAges 18–64 - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT06639074RecruitingPhase 2
Folate receptor dendritic cell vaccine for ovarian cancer
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Scottsdale, ArizonaAges 18 years+
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 551 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.